Peninsula drug company takes big step toward peanut allergy drug approval
Aimmune Therapeutics Inc.'s quest to sell the first biologic drug to treat peanut allergies won a regulatory advisory committee's blessing Friday, moving the company closer to Food and Drug Administration approval.
The action by the nine-member panel doesn't guarantee that the FDA will approve the drug, which would be branded as Palforzia, from Brisbane-based Aimmune (NASDAQ: AIMT). Advisory committee recommendations, however, typically hold great sway with the regulator.
Palforzia is groundbreaking,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Allergy | Allergy & Immunology | Food and Drug Administration (FDA) | Health Management | Peanuts | Pharmaceuticals